Michael H. Mulroy

Board Director

Director

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 1 buy · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (2 ops.)

€31k

▼ Sales (0 ops.)

—

Latest filing published 25 Nov 2024 for Lineage Cell Therapeutics, Inc., €22k. Read the official filing

Filing timeline

BuySale

Michael H. Mulroy

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

100%

T+90 mean return

+34.4%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Michael H. Mulroy: trading record in brief

Michael H. Mulroy (board member) discloses dealings in Lineage Cell Therapeutics, Inc. to SEC (Form 4). We count 3 filings; the first trade dates from 18 June 2021 and the latest from 22 November 2024.

No open-market sale appears; the market trades are 2 purchases worth €31k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 1 option exercise. Since January 2024: 1 purchase and no sales on the market.

The latest filing, published on 25 November 2024, reports an open-market purchase of €22k in Lineage Cell Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.